# Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

> **NCT07035561** · PHASE2 · COMPLETED · sponsor: **Shereen Medhat Mohammed Elsayed Nassar** · enrollment: 30 (actual)

## Conditions studied

- Hypersenstivity Pneumonitis
- ILD

## Interventions

- **DRUG:** Rituximab (Mabthera)

## Key facts

- **NCT ID:** NCT07035561
- **Lead sponsor:** Shereen Medhat Mohammed Elsayed Nassar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07035561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07035561, "Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07035561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*